Which has preferable earnings and valuation, GMRS or LFMD?

GMR Solutions has higher revenue and earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GMR Solutions $5.83B 0.12 $15.12M $0.28 47.75 LifeMD $191.59M 0.87 $14.35M -$0.05 N/A

Is GMRS or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to GMR Solutions' net margin of 0.00%. GMR Solutions' return on equity of 0.00% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets GMR Solutions N/A N/A N/A LifeMD 0.10% -168.23% -31.27%

Does the media refer more to GMRS or LFMD?

In the previous week, LifeMD had 9 more articles in the media than GMR Solutions. MarketBeat recorded 15 mentions for LifeMD and 6 mentions for GMR Solutions. LifeMD's average media sentiment score of 0.76 beat GMR Solutions' score of 0.04 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GMR Solutions 1 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Is FLGT or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets Fulgent Genetics -26.05% -4.93% -4.50% LifeMD 0.10% -168.23% -31.27%

Does the media refer more to FLGT or LFMD?

In the previous week, LifeMD had 12 more articles in the media than Fulgent Genetics. MarketBeat recorded 15 mentions for LifeMD and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.53 beat LifeMD's score of 0.76 indicating that Fulgent Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulgent Genetics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LifeMD 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SRTA or LFMD?

In the previous week, LifeMD had 6 more articles in the media than Strata Critical Medical. MarketBeat recorded 15 mentions for LifeMD and 9 mentions for Strata Critical Medical. LifeMD's average media sentiment score of 0.76 beat Strata Critical Medical's score of 0.67 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Strata Critical Medical 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive LifeMD 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CCRN or LFMD?

In the previous week, LifeMD had 14 more articles in the media than Cross Country Healthcare. MarketBeat recorded 15 mentions for LifeMD and 1 mentions for Cross Country Healthcare. LifeMD's average media sentiment score of 0.76 beat Cross Country Healthcare's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cross Country Healthcare 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

LifeMD (LFMD) Competitors

$3.45 -0.01 (-0.29%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.53 +0.08 (+2.35%)

As of 08/14/2026 07:51 PM Eastern

Compare

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

Should you buy LifeMD stock or one of its competitors? LifeMD's main competitors and comparable companies include GMR Solutions (GMRS), Fulgent Genetics (FLGT), Oncology Institute (TOI), Strata Critical Medical (SRTA), and Cross Country Healthcare (CCRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does LifeMD compare to GMR Solutions?

GMR Solutions (NYSE:GMRS) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, LifeMD had 9 more articles in the media than GMR Solutions. MarketBeat recorded 15 mentions for LifeMD and 6 mentions for GMR Solutions. LifeMD's average media sentiment score of 0.76 beat GMR Solutions' score of 0.04 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GMR Solutions	1 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

35.5% of LifeMD shares are held by institutional investors. 17.2% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

LifeMD has a net margin of 0.10% compared to GMR Solutions' net margin of 0.00%. GMR Solutions' return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GMR Solutions	N/A	N/A	N/A
LifeMD	0.10%	-168.23%	-31.27%

GMR Solutions presently has a consensus price target of $19.22, indicating a potential upside of 43.77%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 119.46%. Given LifeMD's higher possible upside, analysts plainly believe LifeMD is more favorable than GMR Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GMR Solutions	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

GMR Solutions has higher revenue and earnings than LifeMD. LifeMD is trading at a lower price-to-earnings ratio than GMR Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GMR Solutions	$5.83B	0.12	$15.12M	$0.28	47.75
LifeMD	$191.59M	0.87	$14.35M	-$0.05	N/A

Summary

GMR Solutions and LifeMD tied by winning 8 of the 16 factors compared between the two stocks.

How does LifeMD compare to Fulgent Genetics?

Fulgent Genetics (NASDAQ:FLGT) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

LifeMD has a net margin of 0.10% compared to Fulgent Genetics' net margin of -26.05%. Fulgent Genetics' return on equity of -4.93% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-26.05%	-4.93%	-4.50%
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has lower revenue, but higher earnings than Fulgent Genetics. LifeMD is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$322.67M	1.58	-$60.51M	-$2.82	N/A
LifeMD	$191.59M	0.87	$14.35M	-$0.05	N/A

48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 36.2% of Fulgent Genetics shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fulgent Genetics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Fulgent Genetics presently has a consensus price target of $27.50, indicating a potential upside of 48.17%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 119.46%. Given LifeMD's stronger consensus rating and higher probable upside, analysts plainly believe LifeMD is more favorable than Fulgent Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, LifeMD had 12 more articles in the media than Fulgent Genetics. MarketBeat recorded 15 mentions for LifeMD and 3 mentions for Fulgent Genetics. Fulgent Genetics' average media sentiment score of 1.53 beat LifeMD's score of 0.76 indicating that Fulgent Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fulgent Genetics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LifeMD	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulgent Genetics and LifeMD tied by winning 8 of the 16 factors compared between the two stocks.

How does LifeMD compare to Oncology Institute?

Oncology Institute (NASDAQ:TOI) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

LifeMD has lower revenue, but higher earnings than Oncology Institute. LifeMD is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.94	-$60.61M	-$0.37	N/A
LifeMD	$191.59M	0.87	$14.35M	-$0.05	N/A

In the previous week, LifeMD had 14 more articles in the media than Oncology Institute. MarketBeat recorded 15 mentions for LifeMD and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.87 beat LifeMD's score of 0.76 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
LifeMD	Positive

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Oncology Institute has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
LifeMD	0.10%	-168.23%	-31.27%

Oncology Institute currently has a consensus target price of $8.50, indicating a potential upside of 63.90%. LifeMD has a consensus target price of $7.57, indicating a potential upside of 119.46%. Given LifeMD's higher probable upside, analysts clearly believe LifeMD is more favorable than Oncology Institute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

LifeMD beats Oncology Institute on 8 of the 15 factors compared between the two stocks.

How does LifeMD compare to Strata Critical Medical?

Strata Critical Medical (NASDAQ:SRTA) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, LifeMD had 6 more articles in the media than Strata Critical Medical. MarketBeat recorded 15 mentions for LifeMD and 9 mentions for Strata Critical Medical. LifeMD's average media sentiment score of 0.76 beat Strata Critical Medical's score of 0.67 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Strata Critical Medical	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeMD	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Strata Critical Medical has a beta of 2.25, meaning that its share price is 125% more volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

47.4% of Strata Critical Medical shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 15.5% of Strata Critical Medical shares are held by insiders. Comparatively, 17.2% of LifeMD shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Strata Critical Medical presently has a consensus price target of $8.00, suggesting a potential upside of 35.59%. LifeMD has a consensus price target of $7.57, suggesting a potential upside of 119.46%. Given LifeMD's higher probable upside, analysts plainly believe LifeMD is more favorable than Strata Critical Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Strata Critical Medical	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Strata Critical Medical has higher revenue and earnings than LifeMD. Strata Critical Medical is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Strata Critical Medical	$255.98M	1.99	$41.35M	-$0.04	N/A
LifeMD	$191.59M	0.87	$14.35M	-$0.05	N/A

Strata Critical Medical has a net margin of 15.71% compared to LifeMD's net margin of 0.10%. Strata Critical Medical's return on equity of -2.97% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Strata Critical Medical	15.71%	-2.97%	-2.54%
LifeMD	0.10%	-168.23%	-31.27%

Summary

Strata Critical Medical beats LifeMD on 11 of the 17 factors compared between the two stocks.

How does LifeMD compare to Cross Country Healthcare?

Cross Country Healthcare (NASDAQ:CCRN) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Cross Country Healthcare currently has a consensus price target of $12.05, indicating a potential downside of 9.06%. LifeMD has a consensus price target of $7.57, indicating a potential upside of 119.46%. Given LifeMD's stronger consensus rating and higher possible upside, analysts clearly believe LifeMD is more favorable than Cross Country Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cross Country Healthcare	1 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.90
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Cross Country Healthcare has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

96.0% of Cross Country Healthcare shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 6.3% of Cross Country Healthcare shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, LifeMD had 14 more articles in the media than Cross Country Healthcare. MarketBeat recorded 15 mentions for LifeMD and 1 mentions for Cross Country Healthcare. LifeMD's average media sentiment score of 0.76 beat Cross Country Healthcare's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cross Country Healthcare	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a net margin of 0.10% compared to Cross Country Healthcare's net margin of -9.84%. Cross Country Healthcare's return on equity of -0.74% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cross Country Healthcare	-9.84%	-0.74%	-0.54%
LifeMD	0.10%	-168.23%	-31.27%

LifeMD has lower revenue, but higher earnings than Cross Country Healthcare. LifeMD is trading at a lower price-to-earnings ratio than Cross Country Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cross Country Healthcare	$1.00B	0.43	-$94.85M	-$3.05	N/A
LifeMD	$191.59M	0.87	$14.35M	-$0.05	N/A

Summary

LifeMD beats Cross Country Healthcare on 11 of the 16 factors compared between the two stocks.

Get LifeMD News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFMD vs. The Competition

Export

Metric	LifeMD	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$166.29M	$9.84B	$7.02B	$13.06B
Dividend Yield	N/A	2.55%	2.57%	10.45%
P/E Ratio	-68.99	35.17	271.27	25.33
Price / Sales	0.87	5.36	588.55	78.45
Price / Cash	N/A	124.34	70.48	50.90
Price / Book	20.29	3.94	12.92	6.25
Net Income	$14.35M	$309.96M	$3.45B	$347.82M
7 Day Performance	-3.09%	0.09%	1.16%	1.08%
1 Month Performance	-23.84%	-0.33%	1.37%	0.82%
1 Year Performance	-46.35%	19.52%	62.53%	20.99%

LifeMD Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFMD LifeMD	3.308 of 5 stars	$3.45 -0.3%	$7.57 +119.5%	-47.7%	$166.29M	$191.59M	N/A	230	Trending News Analyst Revision
GMRS GMR Solutions	4.7654 of 5 stars	$12.64 +0.5%	$19.22 +52.1%	N/A	$679.47M	N/A	45.14	N/A	News Coverage Earnings Report
FLGT Fulgent Genetics	3.7081 of 5 stars	$19.06 -0.4%	$27.50 +44.3%	-14.6%	$526.64M	$322.67M	N/A	1,315	Positive News
TOI Oncology Institute	3.3626 of 5 stars	$5.19 +1.1%	$8.50 +63.9%	+41.3%	$512.58M	$545.76M	N/A	660	Gap Down
SRTA Strata Critical Medical	2.3827 of 5 stars	$5.94 +2.6%	$8.00 +34.7%	N/A	$500.99M	$197.14M	N/A	130	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFMD) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LifeMD (LFMD) Competitors

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

How does LifeMD compare to GMR Solutions?

Summary

How does LifeMD compare to Fulgent Genetics?

Summary

How does LifeMD compare to Oncology Institute?

Summary

How does LifeMD compare to Strata Critical Medical?

Summary

How does LifeMD compare to Cross Country Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LifeMD (LFMD) Competitors

LFMD vs. GMRS, FLGT, TOI, SRTA, and CCRN

How does LifeMD compare to GMR Solutions?

Does the media refer more to GMRS or LFMD?

Do institutionals and insiders believe in GMRS or LFMD?

Is GMRS or LFMD more profitable?

Do analysts recommend GMRS or LFMD?

Which has preferable earnings and valuation, GMRS or LFMD?

Summary

How does LifeMD compare to Fulgent Genetics?

Is FLGT or LFMD more profitable?

Which has better earnings and valuation, FLGT or LFMD?

Do insiders & institutionals believe in FLGT or LFMD?

Which has more volatility & risk, FLGT or LFMD?

Do analysts rate FLGT or LFMD?

Does the media refer more to FLGT or LFMD?

Summary

How does LifeMD compare to Oncology Institute?

Which has higher valuation and earnings, TOI or LFMD?

Does the media refer more to TOI or LFMD?

Do institutionals and insiders believe in TOI or LFMD?

Which has more risk and volatility, TOI or LFMD?

Is TOI or LFMD more profitable?

Do analysts rate TOI or LFMD?

Summary

How does LifeMD compare to Strata Critical Medical?

Does the media favor SRTA or LFMD?

Which has more volatility & risk, SRTA or LFMD?

Do insiders and institutionals have more ownership in SRTA or LFMD?

Do analysts recommend SRTA or LFMD?

Which has better valuation and earnings, SRTA or LFMD?

Is SRTA or LFMD more profitable?

Summary

How does LifeMD compare to Cross Country Healthcare?

Do analysts prefer CCRN or LFMD?

Which has more risk and volatility, CCRN or LFMD?

Do institutionals & insiders believe in CCRN or LFMD?

Does the media refer more to CCRN or LFMD?

Is CCRN or LFMD more profitable?

Which has higher earnings and valuation, CCRN or LFMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFMD vs. The Competition

LifeMD Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools